The FDA is to quickly review Novartis’s PKC412 (midostaurin) in the blood and bone marrow, acute myeloid leukaemia, with a certain mutation after the drug showed a survival benefit in a lat
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
